Bioethics Financial Statements From 2010 to 2025
| BOTH Stock | USD 0.01 0.00 0.00% |
Check Bioethics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bioethics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Bioethics financial statements analysis is a perfect complement when working with Bioethics Valuation or Volatility modules.
Bioethics |
Bioethics Company Shares Owned By Insiders Analysis
Bioethics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Bioethics Shares Owned By Insiders | 88.53 % |
Most of Bioethics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bioethics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 88% of Bioethics are shares owned by insiders. This is much higher than that of the Financial Services sector and significantly higher than that of the Shell Companies industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.
Bioethics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bioethics's current stock value. Our valuation model uses many indicators to compare Bioethics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bioethics competition to find correlations between indicators driving Bioethics's intrinsic value. More Info.Bioethics is rated below average in return on asset category among its peers. It also is rated below average in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bioethics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bioethics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Bioethics Financial Statements
Investors use fundamental indicators, such as Bioethics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Bioethics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
It intends to seek, investigate, and if warranted acquire an interest in a business opportunity. The company was incorporated in 1990 and is based in Ogden, Utah. Bioethics is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Bioethics Pink Sheet
Bioethics financial ratios help investors to determine whether Bioethics Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bioethics with respect to the benefits of owning Bioethics security.